CRIS Current Research Information System

MONGIORGI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.913
AS - Asia 4.315
EU - Europa 4.020
AF - Africa 478
SA - Sud America 204
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 12
Totale 13.959
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.824
SG - Singapore 1.329
IT - Italia 1.210
VN - Vietnam 1.126
CN - Cina 944
GB - Regno Unito 666
DE - Germania 522
SE - Svezia 510
HK - Hong Kong 260
FR - Francia 200
RU - Federazione Russa 181
IN - India 180
BR - Brasile 145
NL - Olanda 138
TG - Togo 118
JP - Giappone 112
SC - Seychelles 112
IE - Irlanda 110
ZA - Sudafrica 85
CI - Costa d'Avorio 84
FI - Finlandia 84
KR - Corea 74
CA - Canada 58
AT - Austria 57
UA - Ucraina 54
NG - Nigeria 50
BG - Bulgaria 49
EE - Estonia 46
CH - Svizzera 43
HR - Croazia 41
BD - Bangladesh 39
JO - Giordania 39
BE - Belgio 32
ID - Indonesia 29
PK - Pakistan 24
AR - Argentina 22
PH - Filippine 21
PL - Polonia 21
TH - Thailandia 21
TR - Turchia 19
EU - Europa 15
MX - Messico 14
UZ - Uzbekistan 14
TW - Taiwan 13
ES - Italia 12
IQ - Iraq 12
IR - Iran 11
GR - Grecia 10
MY - Malesia 9
EC - Ecuador 8
IL - Israele 8
KE - Kenya 8
AU - Australia 7
EG - Egitto 7
LT - Lituania 7
UY - Uruguay 7
CO - Colombia 6
LB - Libano 6
PY - Paraguay 6
RO - Romania 5
SA - Arabia Saudita 5
MA - Marocco 4
MD - Moldavia 4
PE - Perù 4
TN - Tunisia 4
JM - Giamaica 3
NZ - Nuova Zelanda 3
OM - Oman 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BZ - Belize 2
CL - Cile 2
CR - Costa Rica 2
CY - Cipro 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SS - ???statistics.table.value.countryCode.SS??? 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
Totale 13.946
Salva come PNG Salva come JPEG
Città #
Singapore 955
Ashburn 564
Southend 560
Chandler 456
Bologna 425
Fairfield 367
Santa Clara 288
San Jose 249
Hong Kong 248
Ann Arbor 223
Hanoi 216
Ho Chi Minh City 214
Houston 177
Wilmington 169
Woodbridge 157
Princeton 143
Seattle 142
Beijing 129
Boardman 129
Cambridge 125
Lomé 118
Dong Ket 111
Dublin 110
Dallas 91
Hefei 89
Abidjan 84
Frankfurt am Main 75
Tokyo 72
Milan 68
Lauterbourg 64
Padova 63
Helsinki 60
New York 58
Los Angeles 57
Nanjing 56
Westminster 56
Abeokuta 50
Sofia 49
Council Bluffs 47
Berlin 45
Vienna 41
Jinan 39
Redwood City 39
Amman 38
Seoul 36
Haiphong 35
Buffalo 34
Da Nang 34
Johannesburg 34
Bern 33
Saint Petersburg 33
Turin 33
Medford 31
Bremen 30
Brussels 30
Guangzhou 29
Redondo Beach 29
Changsha 28
Rome 27
Shanghai 27
Moscow 26
Redmond 26
Florence 25
London 25
Munich 25
San Diego 25
Nanchang 24
Shenyang 24
Parma 22
Toronto 21
Montreal 20
Orem 19
Amsterdam 18
Falkenstein 18
Sejong 18
Hebei 17
Jakarta 17
São Paulo 17
Chicago 16
Des Moines 16
Nuremberg 15
Hangzhou 14
San Francisco 14
Udine 14
Brooklyn 13
Lappeenranta 13
Norwalk 13
Paris 13
Rimini 13
Dearborn 12
Falls Church 12
Jiaxing 12
Biên Hòa 11
Düsseldorf 11
Kyiv 11
Modena 11
Tappahannock 11
The Dalles 11
Tianjin 11
Turku 11
Totale 8.684
Salva come PNG Salva come JPEG
Nome #
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 354
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 292
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 291
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 282
Nuclear phosphoinositides: Their regulation and roles in nuclear functions 282
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 263
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 255
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 254
Inositide-Dependent Nuclear Signalling in Health and Disease 252
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 233
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 228
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 228
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 227
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 227
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 225
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 225
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 219
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 217
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 215
Nuclear inositide signaling and cell cycle 213
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 213
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 210
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Nuclear Inositide Signaling via Phospholipase C 206
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 206
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 204
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 202
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 202
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 199
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 198
The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world 193
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 192
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 188
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 187
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 187
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 186
Lamin B1 as a key modulator of the developing and aging brain 176
Nuclear phospholipase C beta1 and cellular differentiation. 175
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 175
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 175
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 174
Protein kinase C involvement in cell cycle modulation 171
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 171
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 170
Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula 167
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells 166
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 164
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 163
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 161
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 160
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 159
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 156
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 154
Understanding the Ultra-Rare Disease Autosomal Dominant Leukodystrophy: an Updated Review on Morpho-Functional Alterations Found in Experimental Models 152
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 152
Nuclear inositide signaling in myelodysplastic syndromes. 151
Recent advances in MDS mutation landscape: Splicing and signalling 150
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 149
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 145
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 141
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 140
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 139
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 139
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 129
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 126
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 125
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 123
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 122
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 116
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 114
null 103
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 103
null 95
null 81
null 72
null 71
Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation 67
Current therapy and new drugs: A road to personalized treatment of myelodysplastic syndromes 62
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 54
Totale 14.292
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021393 0 0 0 0 0 0 0 0 0 0 0 393
2021/20221.707 134 33 81 140 136 77 51 95 74 279 325 282
2022/20232.031 180 265 110 310 169 159 120 151 291 29 130 117
2023/2024840 51 101 82 83 98 121 28 41 74 73 49 39
2024/20252.067 121 272 188 134 350 130 187 90 39 137 97 322
2025/20264.508 363 486 406 276 530 278 551 143 853 341 145 136
Totale 14.292